Human And Financial Capital As Determinants Of Biopharmaceutical IPO De-Listings

ASU Author/Contributor (non-ASU co-authors, if there are any, appear on document)
David Williams, Professor of Healthcare Management (Creator)
Appalachian State University (ASU )
Web Site:

Abstract: The present study combines human capital theory with work on IPOs related to sources of financial capital of recent, publicly traded biopharmaceutical firms and relates this to the de-listing of these firms. The study follows the generally accepted view that more or better quality human capital is a positive factor in individual and firm performance to develop the hypotheses, positing a negative relationship between these factors and IPO de-listing. The results show that to a limited extent firms having CEOs with more or better human capital and strategic alliance partners are associated with biopharmaceutical IPOs’de-listing. The study further finds that de-listing in this industry is due primarily to acquisitions (and not financial distress) and that the findings differ based upon whether examining financial distress or acquisition de-listings. The study draws upon the IPO motivation literature to help explain the results.

Additional Information

Williams, David R. (2012). Human and financial capital as determinants of biopharmaceutical IPO de-listings. Journal of Business Research. Volume 66, Issue 12, December 2013. Publisher version of record available at:
Language: English
Date: 2012
Human capital, Financial capital, Initial public offerings, Strategic alliances

Email this document to